ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541)
:1541
Want to see HK:1541 full AI Analyst Report?
Top Page
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
(1541)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$3.50
▼(-43.09% Downside)
Action:Reiterated
Date:05/01/26
The score is primarily constrained by weak financial performance—large ongoing losses and heavy negative free cash flow despite strong revenue growth. Technicals are also soft with the stock trading below major moving averages, while valuation provides limited support due to a negative P/E and no dividend data.
Positive Factors
Revenue Growth
Sustained high revenue growth indicates successful commercialization and/or advancing pipeline uptake. A strong top-line trajectory can expand addressable market presence and support future margin leverage as R&D and fixed costs are absorbed, improving odds of durable profitability if cash burn is controlled.
Negative Factors
Cash Burn
Persistent, sizable negative operating and free cash flow forces ongoing external financing. Over a multi-quarter horizon this increases dilution risk, diverts management time to capital raises, and makes long-term plans contingent on successful funding or rapid margin improvement to reduce structural cash needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained high revenue growth indicates successful commercialization and/or advancing pipeline uptake. A strong top-line trajectory can expand addressable market presence and support future margin leverage as R&D and fixed costs are absorbed, improving odds of durable profitability if cash burn is controlled.
Read all positive factors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (1541) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.87B
Dividend YieldN/A
Average Volume (3M)4.65M
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue Growth109.02%
EPS Growth36.95%
CountryHK
Employees156
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.53
Shares Outstanding420,477,300
10 Day Avg. Volume5,424,202
30 Day Avg. Volume4,650,789
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.73
Price to Sales (P/S)14.37
P/FCF Ratio-10.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.94
Revenue Forecast (FY)HK$122.00M
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Business Overview & Revenue Model
Company Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, focuses on the development of immuno-oncology therapies. Its lead product candidate is IMM01, a clinical-stage CD47-targeted molecule for the treatment of myelodysplastic synd...
How the Company Makes Money
null...
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 150.30M | 74.15M | 386.00K | 5.69M | 13.81M |
| Gross Profit | 134.99M | 74.15M | 7.70M | 5.69M | 13.81M |
| EBITDA | -203.03M | -295.63M | -355.35M | -384.49M | -718.88M |
| Net Income | -212.92M | -315.86M | -379.46M | -402.89M | -732.95M |
Balance Sheet | |||||
| Total Assets | 1.10B | 922.00M | 874.59M | 839.98M | 892.84M |
| Cash, Cash Equivalents and Short-Term Investments | 1.02B | 752.12M | 608.56M | 635.21M | 668.33M |
| Total Debt | 228.12M | 136.36M | 74.77M | 14.62M | 18.54M |
| Total Liabilities | 308.40M | 243.69M | 126.30M | 60.76M | 2.49B |
| Stockholders Equity | 791.78M | 678.90M | 748.29M | 779.22M | -1.60B |
Cash Flow | |||||
| Free Cash Flow | -197.13M | -138.44M | -370.25M | -261.93M | -315.79M |
| Operating Cash Flow | -195.85M | -128.03M | -367.55M | -238.71M | -190.54M |
| Investing Cash Flow | 2.82M | 37.95M | -294.85M | 49.00K | -108.72M |
| Financing Cash Flow | 397.11M | 258.93M | 331.04M | 179.38M | 793.03M |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Technical Analysis
Negative
6.15
Price Trends
4.70
Negative
4.90
Negative
7.54
Negative
Market Momentum
-0.40
Positive
28.82
Positive
18.77
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1541, the sentiment is Negative. The current price of 6.15 is above the 20-day moving average (MA) of 4.15, above the 50-day MA of 4.70, and below the 200-day MA of 7.54, indicating a bearish trend. The MACD of -0.40 indicates Positive momentum. The RSI at 28.82 is Positive, neither overbought nor oversold. The STOCH value of 18.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1541.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | HK$20.37B | 25.33 | 11.29% | ― | 40.78% | 410.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$8.26B | 9.33 | 24.17% | ― | 154.21% | ― | |
50 Neutral | HK$12.65B | -15.04 | -64.19% | ― | -33.37% | -344.90% | |
47 Neutral | HK$16.57B | -9.24 | -18.69% | ― | 57.92% | -23.76% | |
44 Neutral | HK$2.87B | -8.57 | -32.79% | ― | 109.02% | 36.95% |
* Healthcare Sector Average
HK:1541
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
3.41
-7.19
-67.83%
HK:1672
Ascletis Pharma, Inc.
15.61
8.48
118.93%
HK:2157
Lepu Biopharma Co. Ltd. Class H
4.58
0.10
2.23%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
49.86
34.08
215.97%
HK:2616
CStone Pharmaceuticals
8.02
4.13
106.17%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
6.06
-3.73
-38.10%
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Corporate Events
ImmuneOnco Rotates HK$205m Wealth Product Into Larger HK$212m Placement
May 22, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has fully redeemed a HK$205 million wealth management product from Shenwan Hongyuan Securities (H.K.), booking an estimated unaudited interest gain of about HK$4.97 million. The proceeds will be used a...
ImmuneOnco Begins Phase II Trial of First-in-Class CD47/CD20 Bispecific IMM0306 for Lupus
May 19, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has initiated a Phase II randomized, placebo-controlled clinical trial of its bispecific antibody IMM0306 in systemic lupus erythematosus patients, with about 90 participants to be enrolled across thre...
ImmuneOnco Sets 2026 AGM to Approve Results, Profit Plan and Share Issuance Mandate
Apr 30, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has called its annual general meeting for May 28, 2026, in Shanghai, where shareholders will review 2025 operational and financial performance. They will consider reports from the board and supervisory...
ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma
Mar 30, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has initiated a key late-stage study for its lead asset IMM0306, a bispecific antibody targeting CD47 and CD20 for B-cell malignancies. The company fully owns the global intellectual property and comme...
ImmuneOnco Advances Timdarpacept to Phase III After Strong Leukemia Trial Data
Mar 25, 2026
ImmuneOnco Biopharmaceuticals reported audited annual results for 2025, highlighting significant clinical progress in its oncology pipeline, particularly its core asset timdarpacept. The company positions itself as a specialized cancer drug develo...
ImmuneOnco Completes Key Patient Enrollment in Phase III Trial of Lead Cancer Drug IMM01
Mar 22, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has completed enrollment of 133 patients for the interim analysis of its Phase III clinical trial of IMM01 (Timdarpacept) as a first-line treatment for chronic myelomonocytic leukemia. The trial builds...
ImmuneOnco Sets March 2026 Board Meeting to Approve 2025 Annual Results
Mar 13, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has scheduled a board meeting for 25 March 2026 to review and approve the annual results for the financial year ended 31 December 2025. The board will also consider the publication of these results and...
ImmuneOnco Wins NMPA IND Nod for New Lupus Candidate Amid Share Price Swings
Mar 6, 2026
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. said its business operations and clinical development activities remain normal despite recent unusual share price fluctuations, and the board is not aware of any undisclosed information that would expl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.